TCM
RIGL icon

Triumph Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Triumph Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.82K Buy
+200
New +$6.17K ﹤0.01% 1221
2026
Q1 		– Sell
-200
Closed -$8.57K – 1884
2025
Q4 		$8.57K Buy
+200
New +$7.54K ﹤0.01% 1127

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Triumph Capital Management's RIGL Position: Q2 2026 in Review

Triumph Capital Management opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 200 shares worth $7.82K. The stake represents ﹤0.01% of the portfolio and ranks #1221 among its holdings. This is a return to the name: Triumph Capital Management previously reported a position in RIGL as recently as Q4 2025.

Triumph Capital Management first reported a position in RIGL in Q4 2025 and has held it in 2 quarters since. The position peaked at $8.57K in Q4 2025. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Triumph Capital Management held 200 shares of Rigel Pharmaceuticals worth $7.82K as of Q2 2026.
  • Rigel Pharmaceuticals was a new Triumph Capital Management position in Q2 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1221 holding.
  • Triumph Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Triumph Capital Management's Rigel Pharmaceuticals position peaked at $8.57K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.